Aligos Therapeutics, Inc.
Aligos Therapeutics, Inc. (ALGS): 9 pipeline candidates · 1 upcoming catalyst · ~7 mo cash runway · 4 clinical trials. Updated within the last hour.
BioSniper Score
5-factor signal · derived from public data
7.2 months
D/E 1.03 · 68% dilution
Lead: Phase 2
9 candidates
1 upcoming, next in ~561d
N/A
A transparent, data-derived signal for Aligos Therapeutics, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$31.6M
Cash
$30.2M
Quarterly Burn
$23.1M
Runway
7.2 mo
Revenue
$2.8M
Cash Runway vs Catalysts
A catalyst falls after projected cash runway — potential financing / dilution risk before it hits.
Pipeline (9 candidates)
| Drug | Phase |
|---|---|
| ALG-000184 | Phase 2 |
| ALG-001075 | Phase 1 |
| ALG-055009 | Phase 2 |
| ALG-093940 | Preclinical |
| ALG-097558 | Phase 1 |
| ALG-125755 | Phase 1 |
| alg-170675 | Phase 1 |
| pevifoscorvir | Phase 2 |
| tdf | Phase 2 |
Upcoming Catalysts (1)
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
32
Total value held
$18.2M
| Holder | Shares | Value |
|---|---|---|
| deep track capital, lp | 444,110 | $3.3M |
| alyeska investment group, l.p. | 412,000 | $3.1M |
| vanguard capital management llc | 356,524 | $2.6M |
| marshall wace, llp | 267,135 | $2.0M |
| bank of america corp /de/ | 229,754 | $1.7M |
| summittx capital, l.p. | 148,799 | $1.1M |
| renaissance technologies llc | 100,450 | $746K |
| baker bros. advisors lp | 83,055 | $617K |
| hhlr advisors, ltd. | 76,247 | $567K |
| citadel advisors llc | 54,311 | $404K |
Showing top 10 of 32 institutional holders of Aligos Therapeutics, Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Aligos Therapeutics, Inc.'s pipeline?
Aligos Therapeutics, Inc. (ALGS) has 9 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Aligos Therapeutics, Inc.'s lead drug candidate?
Aligos Therapeutics, Inc.'s most advanced tracked candidate is ALG-000184 (Phase 2) for Chronic hepatitis B (CHB).
What is Aligos Therapeutics, Inc.'s next catalyst?
Aligos Therapeutics, Inc.'s next tracked catalyst is a Phase2_Topline event — "Phase 2 Readout: pevifoscorvir" — expected December 31, 2027.
What is Aligos Therapeutics, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Aligos Therapeutics, Inc. has approximately 7.2 months of cash runway.
What is Aligos Therapeutics, Inc.'s market capitalization?
Aligos Therapeutics, Inc.'s market capitalization is approximately $31.6M.
Get the full picture on Aligos Therapeutics, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.